Home

COLUMN GROUP L P

CIK 1347769 · last filed 2023-11-17

COLUMN GROUP L P is a corporate insider who has filed 21 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing shows the insider bought $155.1K of NGM on Nov 17, 2023. Across all open-market trades the lifetime net is +$67.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $37.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$37.87M

Companies

3

Total Filings

21

Lifetime Open-Market Net

$67.18M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NGM BIOPHARMACEUTICALS INC (NGM) Delisted Director 12,053,195 $1.54 $18.56M $67.18M 19 2023-11-17
NRIX 10%+ Owner 1,533,716 $24.69 $37.87M $0 1 2021-05-07
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted 10%+ Owner 2,607,060 $33.99 $88.61M $0 1 2020-12-16

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-11-17 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +226,310 $155.1K EDGAR
2023-02-01 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +368,544 $1.84M EDGAR
2023-01-25 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +19,800 $99.0K EDGAR
2023-01-23 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +381,390 $1.91M EDGAR
2023-01-23 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +76,278 $381.2K EDGAR
2022-11-07 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +1,391,480 $6.84M EDGAR
2022-11-07 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +278,296 $1.37M EDGAR
2022-10-31 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +153,754 $747.3K EDGAR
2022-10-27 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +247,640 $1.19M EDGAR
2022-06-06 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +273,600 $3.57M EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.